When: Trim proceeds available

Then: Enter MRK/JNJ via limit orders -2% to -3% from spot

REDUCE 30% into rallies toward 28.50-29; maintain smaller core position; tighten stop to 26.50-26.80 (above 200 SMA)

• Seagen impairments represent $8.9B write-downs on $43B purchase, with $118B goodwill/intangibles = 60% of total assets
• Forward P/E of 9.67 requires sequential execution across pipeline, earnings, no further impairments, and macro
• Dividend coverage: $9.77B dividends vs $9.08B free cash flow = 7% shortfall; dividend funded by debt at multi-decade high rates
• $63B debt load with rising carry costs; rate environment is clear headwind for high-dividend equities
• Eliquis generates ~$6.5B annual revenue facing generic erosion - overhang not yet hitting income statement
• Technical indicators neutral: RSI at 52, MACD below signal line, price on 10 EMA without conviction, volatility compression ambiguous
• Sentiment silence signals no catalyst rather than contrarian bullish signal
• Macro: 96% probability of no Fed cuts, 10-year yields at 2002 highs; multiple expansion thesis requires macro pivot
• 36x trailing earnings unjustified given concentrated risk across earnings, patent cliff, and macro calls
• Responsible approach: trim into strength, preserve core dividend exposure, wait for earnings confirmation or macro turn

→ vs aggressive: Seagen impairments are not accounting noise but management's own admission of capital allocation error ($43B spent, $118B goodwill = 60% of assets)

→ vs aggressive: Forward P/E of 9.67 requires multiple sequential variables to go right; not asymmetric risk but concentrated narrative risk

→ vs aggressive: Dividend covered by debt issuance puts company on a clock; 7% FCF shortfall with $63B debt load at multi-decade high rates creates dividend cut risk

→ vs aggressive: Eliquis patent cliff is actively approaching income statement, not merely a distant overhang; $6.5B revenue at risk cannot be assumed replaced dollar-for-dollar

→ vs aggressive: Technical setup is not a coiled spring; MACD negative, RSI at 52 is neutral, trend not confirmed - wait for confirmation before adding exposure

→ vs aggressive: Sentiment silence is stagnant rather than bullish; absence of chatter means no buyers, not no sellers

→ vs aggressive: Macro call stacked on top of earnings and patent cliff calls is not concentration risk management; betting against 96% implied probability is a separate position

→ vs neutral: Traders' 30-50% reduction plan is too aggressive; prefer starting at 30% reduction executed patiently into rallies

MODERATE the SELL to a 20-25% trim, retaining a core position; execute into rallies toward $28.50-$29.00 over 2-4 weeks; stop at $25.80

• Seagen impairments are a yellow flag on management M&A discipline ($8.9B write-down on $43B acquisition) that inform the multiple but do not justify panic-selling
• Forward P/E of 9.67x already embeds earnings risk; gap versus TTM P/E of 36.8x is why stock has held $27.50 and reclaimed 50 SMA
• FCF shortfall of $700M against $9.77B dividend obligation is a slow-burning vulnerability requiring monitoring, not imminent dividend cut
• Eliquis LOE hits 2026-2027; acute erosion is Q2-Q3 post-LOE, not Q3; early script trend data available but full hit not yet
• Technical structure intact: +8.3% above rising 200 SMA at $25.86, 50 SMA successfully defended; conservative $26.50 stop triggers on normal volatility
• Macro environment is bad but not collapsing: 96% no-cut probability and 6% recession probability make aggressive positioning premature
• Trimming preserves asymmetric upside from attractive forward P/E and intact technicals without making three simultaneous macro/earnings/patent calls
• Re-entry triggers: MACD histogram positive with price closing above $28.30 on rising volume, or Q3 earnings clean read on Eliquis scripts and Seagen execution

→ vs aggressive: Forward P/E case already partially embedded in current price; betting against $28.50-$29.00 rally target requires three simultaneous macro and earnings calls against prevailing tape

→ vs aggressive: Eliquis 'priced in' defense is dangerous; generic arrival historically crushes stocks vs. theoretical overhang; though LOE timing is 2026-2027, not imminent

→ vs aggressive: Technical 'coiled spring' resolves upward only 55-60% historically, not 90%+ confidence being projected

→ vs conservative: Dividend coverage gap does not imply imminent cut; cut requires multi-quarter execution failure, not continued coverage gaps

→ vs conservative: Tight $26.50 stop would trigger on normal 50 SMA retest; $25.80 stop below 200 SMA is appropriate for thesis-level stop on defensive name